Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Kenneth W. Mahaffey"'
Publikováno v:
Future Cardiol
SGLT2 inhibitors have risen to prominence in recent years as Type 2 diabetes mellitus medications with favorable effects on cardiovascular (CV) and renal outcomes. Canagliflozin is a US FDA-approved SGLT2 inhibitor that has demonstrated CV and renal
Autor:
Kenneth W. Mahaffey, Kent Y Feng
Publikováno v:
Future Cardiology. 16:89-102
Inadequate antiplatelet effects can result in substantial morbidity and mortality in patients with acute coronary syndrome and percutaneous coronary intervention (PCI). Cangrelor is a rapid onset and potent intravenous P2Y12 inhibitor that has been s